Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.
A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.